51. Scleroderma Clinical trials / Disease details
Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02370784 (ClinicalTrials.gov) | February 2015 | 26/1/2015 | Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma | The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis | Scleroderma | Drug: atorvastatin;Drug: Placebo | Robyn T. Domsic, MD, MPH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | 70 Years | All | 24 | Phase 2 | United States |
| 2 | EUCTR2005-003775-21-GB (EUCTR) | 14/08/2008 | 10/11/2005 | Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosis | Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis - Atorvastatin in systemic sclerosis | Systemic sclerosis (also termed 'scleroderma') | Trade Name: Lipitor Product Name: Lipitor | Salford Royal Hospitals NHS Trust | University of Manchester | Not Recruiting | Female: yes Male: yes | 36 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |